(Q34372166)

1 August 2017

0 references

Lapatinib, trastuzumab or the combination added to preoperative chemotherapy for breast cancer: a meta-analysis of randomized evidence (English)

1 reference

1 August 2017

0 references

1 reference

1 reference

Antonis Valachis

1

1 reference

1 August 2017

Andreas Nearchou

series ordinal

2

1 reference

1 August 2017

Pehr Lind

series ordinal

3

1 reference

1 August 2017

Davide Mauri

series ordinal

4

1 reference

1 August 2017

language of work or name

English

0 references

publication date

9 August 2012

1 reference

Breast Cancer Research and Treatment

1 August 2017

published in

1 reference

1 August 2017

volume

135

1 reference

1 August 2017

issue

3

1 reference

1 August 2017

page(s)

655-662

1 reference

Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2189-Z

Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2189-Z

Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2189-Z

The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2189-Z

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2189-Z

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2189-Z

Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2189-Z

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2189-Z

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2189-Z

Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2189-Z

Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2189-Z

Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2189-Z

Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2189-Z

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2189-Z

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2189-Z

Lapatinib-associated toxicity and practical management recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2189-Z

New approaches to antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2189-Z

10.1007/S10549-012-2189-Z

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

1 August 2017

1003281536

0 references

1 reference